| Basic Materials | 4.58% | |
|---|---|---|
| Consumer Cyclical | 0.00% | |
| Financial Services | 0.00% | |
| Real Estate | 0.00% | |
| Consumer Defensive | 0.00% | |
| Healthcare | 86.13% |
| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 29.55 | -0.20 (-0.68%) | 20.57 - 30.43 | 41.2 thousand (Above Avg) |
Market data as of 2:41PM 05/22/13. Quotes are delayed by at least 15 min.
The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
| Open | 29.96 |
|---|---|
| Previous Close | 29.75 |
| Day's Range | 29.55 - 30.43 |
| Avg Volume (10 Day) | 30.0K |
| Total Assets | $154.04M |
| Expense Ratio | 0.64% |
| Yield (Trailing 12 Mo.) | 0.00% |
| Fund Inception | 06/23/2005 |
| Timeframe | PBE | S&P 500 | Health |
|---|---|---|---|
| 1 Month | 7.82% | 1.93% | 3.38% |
| 3 Month | 14.00% | 7.18% | 10.04% |
| Year-to-Date | 23.62% | 12.74% | 17.90% |
| 1 Year | 26.95% | 16.89% | 26.16% |
| 3 Year | 12.84% | 12.80% | 17.80% |
| 5 Year | 9.83% | 5.21% | 13.29% |
| 10 Year | -- | 7.88% | 8.84% |
| Since Inception | 8.74% | 10.38% | -- |
| Basic Materials | 4.58% | |
|---|---|---|
| Consumer Cyclical | 0.00% | |
| Financial Services | 0.00% | |
| Real Estate | 0.00% | |
| Consumer Defensive | 0.00% | |
| Healthcare | 86.13% |
| Utilities | 0.00% | |
|---|---|---|
| Communication Services | 0.00% | |
| Energy | 0.00% | |
| Industrials | 0.00% | |
| Technology | 9.29% |
| Valuation | PBE | Category Range |
|---|---|---|
| Price/Earnings | 22.09 | |
| Price/Book | 4.60 | |
| Price/Sales | 5.31 | |
| Price/Cash Flow | 18.76 | |
| Dividend Yield | 0.5 | |
| LT Earnings | 15.66 | |
| Historical Earnings | 19.26 | |
| Sales Growth | 11.55 | |
| Cash-Flow Growth | 6.05 | |
| Book-Value Growth | 10.94 |
| Management Style | |||
|---|---|---|---|
| Large Cap | |||
| Medium Cap | |||
| Small Cap | |||
![]() | ![]() | ![]() |

| Rating | vs Category | |
|---|---|---|
| Overall | ![]() | |
| Risk | Above Avg | |
| Return | Below Avg |
| Beta | 0.98 |
|---|---|
| Standard Deviation | 19.27 |
| Alpha | 3.63 |
| Sharpe Ratio | 0.72 |
| Mean | 14.84 |
| R-Squared | 71.41 |
| Pretax Return | 12.84% |
|---|---|
| Tax-adjusted Return | 12.84% |
| Tax Cost Ratio | 0.00% |
| Potential Cap Gains | -66.57% |